The primary objective of this study is to measure the infection rate and presentation pattern in first 12 months of therapy with elranatamab as standard clinical practice in adult patients with Relapsed/Refractory Multiple Myeloma.
adult patients (age >18 years) with no upper age limit
confirmed Relapsed and Refractory Multiple Myeloma (RRMM) according to IMWG criteria (demonstrated disease progression on the last therapy (progressed on or within 60 days of last therapy).
Patients must have received at least three (3) prior lines of therapy, including at least: one Immunomodulatory agent (e.g., Lenalidomide, Pomalidomide), one Proteasome Inhibitor (e.g., Bortezomib, Carfilzomib), one Anti-CD38 Monoclonal Antibody (e.g., Daratumumab, Isatuximab).
Treatment with elranatamab within standard clinical practice
None
Adult patients with Relapsed/Refractory Multiple Myeloma treated with elranatamab as standard clinical practice
Case-only
Prospective
Not listed
Infection rate in the first 12 months of therapy with elranatamab
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
